鼠传疾病相关疫苗研究进展

doi:10.11853/j.issn.1003.8280.2022.05.027

摘要/Abstract

摘要： 鼠传疾病大多是人兽共患的自然疫源性疾病。啮齿动物因种类多、分布广、繁殖能力强而危害严重，随着城市化进程加快、啮齿动物栖息地破坏、人类与啮齿动物接触可能性增加等，多种鼠传疾病的流行区域不断扩大，对鼠传疾病的防治带来严峻的考验和挑战。疫苗接种是最有效的预防和控制疾病的手段，相关疫苗的研发生产大大缓解了国家医疗卫生系统的压力。当前鼠传疾病相关疫苗包括传统疫苗（灭活疫苗、减毒活疫苗）和新型疫苗（基因工程疫苗）。该文系统概述了鼠传疾病疫苗研发的主要进展和未来展望。

关键词: 鼠传疾病, 啮齿动物, 疫苗

Abstract: Most rodent-borne diseases are naturally occurring zoonotic infections.Rodents pose a serious threat due to their diverse species,wide distribution,and strong reproductive ability.With accelerating urbanization,expanding rodent habitat destruction,and increasing human-rodent contact,the epidemic areas of many rodent-borne diseases are enlarging,which poses greatly challenges to the prevention and control of rodent-borne diseases.Vaccination is the most effective means of disease prevention and control.The development and production of vaccines has greatly eased the pressure on the national health care system.Current vaccines for rodent-borne diseases include traditional (inactivated and live attenuated vaccines) and new (genetically engineered vaccines) types.This paper systematically summarized the progress and future prospects of vaccine development for rodent-borne diseases.

Key words: Rodent-borne disease, Rodent, Vaccine

中图分类号:

R184.3

冯群岭, 刘敏, 白英, 黄亚楠, 李颜, 王丹, 史文龙, 王思奇, 司海瑞, 王红红. 鼠传疾病相关疫苗研究进展[J]. 中国媒介生物学及控制杂志, 2022, 33(5): 760-764.

FENG Qun-ling, LIU Min, BAI Ying, HUANG Ya-nan, LI Yan, WANG Dan, SHI Wen-long, WANG Si-qi, SI Hai-rui, WANG Hong-hong. Advances in research on vaccines for rodent-borne diseases[J]. Chinese Journal of Vector Biology and Control, 2022, 33(5): 760-764.

参考文献

[1] Rabiee MH,Mahmoudi A,Siahsarvie R,et al. Rodent-borne diseases and their public health importance in Iran[J]. PLoS Negl Trop Dis,2018,12(4):e0006256. DOI:10.1371/journal.pntd.0006256.
[2] Griffiths J,Yeo HL,Yap G,et al. Survey of rodent-borne pathogens in Singapore reveals the circulation of Leptospira spp.,Seoul hantavirus,and Rickettsia typhi[J]. Sci Rep,2022,12(1):2692. DOI:10.1038/s41598-021-03954-w.
[3] 刘起勇.气候变化对中国媒介生物传染病的影响及应对:重大研究发现及未来研究建议[J].中国媒介生物学及控制杂志,2021,32(1):1-11. DOI:10.11853/j.issn.1003.8280.2021. 01.001. Liu QY. Impact of climate change on vector-borne diseases and related response strategies in China:Major research findings and recommendations for future research[J]. Chin J Vector Biol Control,2021,32(1):1-11. DOI:10.11853/j.issn.1003.8280. 2021.01.001.(in Chinese)
[4] Morris SR. Development of a recombinant vaccine against aerosolized plague[J]. Vaccine,2007,25(16):3115-3117. DOI:10.1016/j.vaccine.2007.01.071.
[5] 刘丽,汪巨峰,李波.鼠疫疫苗的研究现状和进展[J].中国药学杂志,2013,48(12):945-949. DOI:10.11669/cpj.2013.12.001. Liu L,Wang JF,Li B. Current status and progress of research on plague vaccine[J]. Chin Pharm J,2013,48(12):945-949. DOI:10.11669/cpj.2013.12.001.(in Chinese)
[6] Fitts EC,Andersson JA,Kirtley ML,et al. New insights into autoinducer-2 signaling as a virulence regulator in a mouse model of pneumonic plague[J]. mSphere,2016,1(6):e00342-16. DOI:10.1128/mSphere.00342-16.
[7] Zauberman A,Vagima Y,Tidhar A,et al. Host iron nutritional immunity induced by a live Yersinia pestis vaccine strain is associated with immediate protection against plague[J]. Front Cell Infect Microbiol,2017,7:277. DOI:10.3389/fcimb.2017. 00277.
[8] Demeure CE,Derbise A,Carniel E. Oral vaccination against plague using Yersinia pseudotuberculosis[J]. Chem Biol Interact,2017,267:89-95. DOI:10.1016/j.cbi.2016.03.030.
[9] Quenee LE,Ciletti NA,Elli D,et al. Prevention of pneumonic plague in mice,rats,guinea pigs and non-human primates with clinical grade rV10,rV10-2 or F1-V vaccines[J]. Vaccine,2011,29(38):6572-6583. DOI:10.1016/j.vaccine.2011.06.119.
[10] Hu JL,Jiao L,Hu YM,et al. One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults:An extended open-label study[J]. Hum Vaccin Immunother,2018,14(11):2701-2705. DOI:10.1080/21645515.2018.1486154.
[11] 李学荣,余新炳.核酸疫苗及其免疫机制研究[J].中国人兽共患病杂志,2000,16(6):82-86. DOI:10.3969/j.issn.1002-2694. 2000.06.029. Li XR,Yu XB. Research on nucleic acid vaccine and its immunization mechanism[J]. Chin J Zoonoses,2000,16(6):82-86. DOI:10.3969/j.issn.1002-2694.2000.06.029.(in Chinese)
[12] 焦磊,吴智远,王婷,等.鼠疫疫苗Ⅱa期临床血清对小鼠的被动保护水平及其与抗体效价的相关性分析[J].微生物学免疫学进展,2017,45(6):9-12. DOI:10.13309/j.cnki.pmi.2017. 06.002. Jiao L,Wu ZY,Wang T,et al. F1 and V antibody levels in correlation to mice protection passively adopted from human serum immunized by plague vaccine[J]. Prog Microbiol Immunol,2017,45(6):9-12. DOI:10.13309/j.cnki.pmi.2017. 06.002.(in Chinese)
[13] 陈化新.中国肾综合征出血热疫苗大规模应用研究[J].中华流行病学杂志,2002,23(2):145-147. DOI:10.3760/j.issn:0254-6450.2002.02.019. Chen HX. Large-scale application study of hemorrhagic fever vaccine for renal syndrome in China[J]. Chin J Epidemiol,2002,23(2):145-147. DOI:10.3760/j.issn:0254-6450.2002.02.019.(in Chinese)
[14] Sohn YM,Rho HO,Park MS,et al. Primary humoral immune responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax^®):Consideration of active immunization in South Korea[J]. Yonsei Med J,2001,42(3):278-284. DOI:10.3349/ymj.2001.42.3.278.
[15] 张锦鹏,张冠文,宣国云,等.溶酶体靶向的汉坦病毒包膜糖蛋白DNA疫苗的体液免疫评价和攻毒保护效果[J].中国免疫学杂志,2018,34(3):331-334. DOI:10.3969/j.issn.1000-484X.2018.03.003. Zhang JP,Zhang GW,Xuan GY,et al. Humoral immunity evaluation and virual challenge of lysosomal targeted hantavirus envelope glycoprotein DNA vaccine[J]. Chin J Immunol,2018,34(3):331-334. DOI:10.3969/j.issn.1000-484X.2018.03.003.(in Chinese)
[16] Brown KS,Safronetz D,Marzi A,et al. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus[J]. J Virol,2011,85(23):12781-12791. DOI:10.1128/JVI.00794-11.
[17] Hooper J,Paolino KM,Mills K,et al. A phase 2a randomized,double-blind,dose-optimizing study to evaluate the immunogenicity and safety of a bivalent DNA vaccine for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation[J]. Vaccines,2020,8(3):377. DOI:10.3390/vaccines8030377.
[18] Adler B. Vaccines against leptospirosis[J]. Curr Top Microbiol Immunol,2015,387:251-272. DOI:10.1007/978-3-662-45059-8_10.
[19] Adler B,de la Peña Moctezuma A. Leptospira and leptospirosis[J]. Vet Microbiol,2010,140(3/4):287-296. DOI:10.1016/j.vetmic.2009.03.012.
[20] Srikram A,Zhang KK,Bartpho T,et al. Cross-protective immunity against leptospirosis elicited by a live,attenuated lipopolysaccharide mutant[J]. J Infect Dis,2011,203(6):870-879. DOI:10.1093/infdis/jiq127.
[21] Conrad NL,McBride FWC,Souza JD,et al. LigB subunit vaccine confers sterile immunity against challenge in the hamster model of leptospirosis[J]. PLoS Negl Trop Dis,2017,11(3):e0005441. DOI:10.1371/journal.pntd.0005441.
[22] Forster KM,Hartwig DD,Seixas FK,et al. A conserved region of leptospiral immunoglobulin-like A and B proteins as a DNA vaccine elicits a prophylactic immune response against leptospirosis[J]. Clin Vaccine Immunol,2013,20(5):725-731. DOI:10.1128/CVI.00601-12.
[23] da Cunha CEP,Bettin EB,Bakry AFAAY,et al. Evaluation of different strategies to promote a protective immune response against leptospirosis using a recombinant LigA and LigB chimera[J]. Vaccine,2019,37(13):1844-1852. DOI:10.1016/j.vaccine. 2019.02.010.
[24] Garba B,Bahaman AR,Zakaria Z,et al. Antigenic potential of a recombinant polyvalent DNA vaccine against pathogenic leptospiral infection[J]. Microb Pathog,2018,124:136-144. DOI:10.1016/j.micpath.2018.08.028.
[25] Shen AK,Mead PS,Beard CB. The Lyme disease vaccine:A public health perspective[J]. Clin Infect Dis,2011,52 Suppl 3:S247-252. DOI:10.1093/cid/ciq115.
[26] Dattwyler RJ,Gomes-Solecki M. The year that shaped the outcome of the OspA vaccine for human Lyme disease[J]. npj Vaccines,2022,7(1):10. DOI:10.1038/s41541-022-00429-5.
[27] Hahn BL,Padmore LJ,Ristow LC,et al. Live attenuated Borrelia burgdorferi targeted mutants in an infectious strain background protect mice from challenge infection[J]. Clin Vaccine Immunol,2016,23(8):725-731. DOI:10.1128/CVI.00302-16.
[28] Ding W,Huang XL,Yang XH,et al. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA[J]. J Mol Biol,2000,302(5):1153-1164. DOI:10.1006/jmbi.2000. 4119.
[29] Vogt NA,Sargeant JM,Mackinnon MC,et al. Efficacy of Borrelia burgdorferi vaccine in dogs in North America:A systematic review and meta-analysis[J]. J Vet Intern Med,2019,33(1):23-36. DOI:10.1111/jvim.15344.
[30] Guibinga GH,Sahay B,Brown H,et al. Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine[J]. Hum Vaccin Immunother,2020,16(9):2114-2122. DOI:10.1080/21645515.2020.1789408.
[31] 贺琪楠,尹家祥.鼠型斑疹伤寒流行现状及其影响因素[J].中国热带医学,2019,19(8):790-793. DOI:10.13604/j.cnki.46-1064/r.2019.08.19. He QN,Yin JX. Epidemic situation and influential factors of murine typhus[J]. China Trop Med,2019,19(8):790-793. DOI:10.13604/j.cnki.46-1064/r.2019.08.19.(in Chinese)
[32] Osterloh A. The neglected challenge:Vaccination against rickettsiae[J]. PLoS Negl Trop Dis,2020,14(10):e0008704. DOI:10.1371/journal.pntd.0008704.
[33] Walker DH. The realities of biodefense vaccines against Rickettsia[J]. Vaccine,2009,27 Suppl 4:D52-D55. DOI:10. 1016/j.vaccine.2009.07.045.
[34] Choi S,Jeong HJ,Hwang KJ,et al. A recombinant 47-kDa outer membrane protein induces an immune response against Orientia tsutsugamushi strain Boryong[J]. Am J Trop Med Hyg,2017,97(1):30-37. DOI:10.4269/ajtmh.15-0771.
[35] Kim HI,Ha NY,Kim G,et al. Immunization with a recombinant antigen composed of conserved blocks from TSA56 provides broad genotype protection against scrub typhus[J]. Emerg Microbes Infect,2019,8(1):946-958. DOI:10.1080/22221751. 2019.1632676.
[36] Cho H,Lee WH,Kim YK,et al. Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus[J]. Biochem Biophys Res Commun,2020,523(3):602-607. DOI:10.1016/j.bbrc.2020.01.014.
[37] Song SW,Kim KT,Ku YM,et al. Clinical role of interstitial pneumonia in patients with scrub typhus:A possible marker of disease severity[J]. J Korean Med Sci,2004,19(5):668-673. DOI:10.3346/jkms.2004.19.5.668.
[38] Park SM,Gu MJ,Ju YJ,et al. Intranasal vaccination with outer-membrane protein of Orientia tsutsugamushi induces protective immunity against Scrub Typhus[J]. Immune Netw,2021,21(2):e14. DOI:10.4110/in.2021.21.e14.
[39] Liu RR,Ma HW,Shu JY,et al. Vaccines and therapeutics against Hantaviruses[J]. Front Microbiol,2020,10:2989. DOI:10.3389/fmicb.2019.02989.
[40] Mir S. Hantavirus induced kidney disease[J]. Front Med (Lausanne),2022,8:795340. DOI:10.3389/fmed.2021.795340.